These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 30547287)

  • 21. CNTO6785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study.
    Mease PJ; Jeka S; Jaller JJ; Kitumnuaypong T; Louthrenoo W; Mann H; Matsievskaia G; Soriano ER; Jia B; Wang C; Nie J; Hsia E
    J Rheumatol; 2018 Jan; 45(1):22-31. PubMed ID: 29093159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis.
    Reis J; Vender R; Torres T
    BioDrugs; 2019 Aug; 33(4):391-399. PubMed ID: 31172372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.
    Genovese MC; Greenwald M; Cho CS; Berman A; Jin L; Cameron GS; Benichou O; Xie L; Braun D; Berclaz PY; Banerjee S
    Arthritis Rheumatol; 2014 Jul; 66(7):1693-704. PubMed ID: 24623718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody blockade of IL-17 family cytokines in immunity to acute murine oral mucosal candidiasis.
    Whibley N; Tritto E; Traggiai E; Kolbinger F; Moulin P; Brees D; Coleman BM; Mamo AJ; Garg AV; Jaycox JR; Siebenlist U; Kammüller M; Gaffen SL
    J Leukoc Biol; 2016 Jun; 99(6):1153-64. PubMed ID: 26729813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated autoantibodies against interleukin-17F correlate with disease activity in patients with early rheumatoid arthritis.
    Yang L; Bai L; Wei F; Liu Y; Sun L; Wang W; Liu X; Wang Y
    Int J Rheum Dis; 2016 Jul; 19(7):644-50. PubMed ID: 26087054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY.
    Boyapati A; Msihid J; Fiore S; van Adelsberg J; Graham NM; Hamilton JD
    Arthritis Res Ther; 2016 Oct; 18(1):225. PubMed ID: 27716324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study.
    Nemoto O; Furue M; Nakagawa H; Shiramoto M; Hanada R; Matsuki S; Imayama S; Kato M; Hasebe I; Taira K; Yamamoto M; Mihara R; Kabashima K; Ruzicka T; Hanifin J; Kumagai Y
    Br J Dermatol; 2016 Feb; 174(2):296-304. PubMed ID: 26409172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel immunoassay to measure total serum lymphotoxin-α levels in the presence of an anti-LTα therapeutic antibody.
    Young J; Nguyen A; Qiu ZJ; Ying Y; Gao X; Reed C; Chuntharapai A; Deng R; Lutman J; Grogan J; Wong WL; DeForge L
    J Immunol Methods; 2015 Sep; 424():91-9. PubMed ID: 26009247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of Th17 cells in patients with relapsing-remitting multiple sclerosis: interleukin-17A and interleukin-17F serum levels.
    Babaloo Z; Aliparasti MR; Babaiea F; Almasi S; Baradaran B; Farhoudi M
    Immunol Lett; 2015 Apr; 164(2):76-80. PubMed ID: 25625963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population Pharmacokinetics of the TNF-α and IL-17A Dual-Variable Domain Antibody ABT-122 in Healthy Volunteers and Subjects With Psoriatic or Rheumatoid Arthritis: Analysis of Phase 1 and 2 Clinical Trials.
    Khatri A; Othman AA
    J Clin Pharmacol; 2018 Jun; 58(6):803-813. PubMed ID: 29364523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers.
    Cardinal M; Kantaridis C; Zhu T; Sun P; Pittman DD; Murphy JE; Arkin S
    J Thromb Haemost; 2018 Sep; 16(9):1722-1731. PubMed ID: 29908043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy After Single and Multiple Dosings of LY3016859 in Healthy Subjects and Patients With Diabetic Nephropathy.
    Sloan-Lancaster J; Raddad E; Deeg MA; Eli M; Flynt A; Tumlin J
    Clin Pharmacol Drug Dev; 2018 Sep; 7(7):759-772. PubMed ID: 29385323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of rheumatoid arthritis.
    Murota A; Suzuki K; Kassai Y; Miyazaki T; Morita R; Kondo Y; Takeshita M; Niki Y; Yoshimura A; Takeuchi T
    Cytokine; 2016 Feb; 78():87-93. PubMed ID: 26700586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, Tolerability, and Pharmacodynamics of ABT-122, a Tumor Necrosis Factor- and Interleukin-17-Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis.
    Fleischmann RM; Wagner F; Kivitz AJ; Mansikka HT; Khan N; Othman AA; Khatri A; Hong F; Jiang P; Ruzek M; Padley RJ
    Arthritis Rheumatol; 2017 Dec; 69(12):2283-2291. PubMed ID: 28941216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gingival crevicular fluid, serum levels of receptor activator of nuclear factor-κB ligand, osteoprotegerin, and interleukin-17 in patients with rheumatoid arthritis and osteoporosis and with periodontal disease.
    Gümüş P; Buduneli E; Bıyıkoğlu B; Aksu K; Saraç F; Nile C; Lappin D; Buduneli N
    J Periodontol; 2013 Nov; 84(11):1627-37. PubMed ID: 23327689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IL-17 inhibitors for psoriasis.
    Paek SY; Frieder J; Kivelevitch D; Menter MA
    Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and validation of panoptic Meso scale discovery assay to quantify total systemic interleukin-6.
    Chaturvedi S; Siegel D; Wagner CL; Park J; van de Velde H; Vermeulen J; Fung MC; Reddy M; Hall B; Sasser K
    Br J Clin Pharmacol; 2015 Oct; 80(4):687-97. PubMed ID: 25847183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study.
    Genovese MC; Van den Bosch F; Roberson SA; Bojin S; Biagini IM; Ryan P; Sloan-Lancaster J
    Arthritis Rheum; 2010 Apr; 62(4):929-39. PubMed ID: 20131262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.
    Albach FN; Wagner F; Hüser A; Igel J; Joseph D; Hilbert J; Schoelch C; Padula SJ; Steffgen J
    Eur J Clin Pharmacol; 2018 Feb; 74(2):161-169. PubMed ID: 29127458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.